X
[{"orgOrder":0,"company":"BioInvent","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"BioInvent Receives \u20ac2 million Milestone from Daiichi Sankyo","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"BioInvent"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia IND Application for CAN04 Approved by FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Cantargia AB"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Submits Application to Start New Clinical Trial Investigating Antibody CAN04 and FOLFIRINOX in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Cantargia AB"},{"orgOrder":0,"company":"Cantargia AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cantargia Reaches Recruitment Milestone And Focuses Nadunolimab Development On Upcoming Randomized Studies","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Cantargia AB"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir Receives Regulatory Approval from MHRA for Phase 1\/2a Combination Study with MIV-818","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Medivir"},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Birinapant Clinical Study Initiated By IGM Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Medivir"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunicum AB: Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Mendus"},{"orgOrder":0,"company":"Mendus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mendus To Report Positive Clinical And Preclinical Data In Ovarian Cancer At The European Society Of Gynaecological Oncology 2022 Congress","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Mendus"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech Provides Status Update in the Portfolio Projects","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Active Biotech"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"D","amount":"$71.0 million","upfrontCash":"Undisclosed","newsHeadline":"Active Biotech Receive Milestone Payment From Neotx","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Active Biotech"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Active Biotech: Tasquinimod Clinical Development in Multiple Myeloma Advances Into Combination Therapy Following Completion of The Initial Phase of The Ongoing Trial in The US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Active Biotech"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data on Naptumomab Estafenatox Enhancing CAR-T Cells Potency Presented by Active Biotech\u2019s Partner NeoTX at SITC 2021","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Active Biotech"},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Additional patients treated in LIDDS clinical study NZ-DTX-001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Lidds"},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Prostate Cancer Study to Be Initiated at Uppsala University Hospital with Nano Zolid Technology\u00ae","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Lidds"},{"orgOrder":0,"company":"Lidds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NanoZolid\u00ae-formulated Docetaxel is Safe and Tolerable Showing Signs of Clinical Efficacy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Lidds"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"SAKK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Oasmia Pharmaceutical"},{"orgOrder":0,"company":"Oasmia Pharmaceutical","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oasmia Signs Manufacturing Agreement with Lonza for Ovarian Cancer Drug Candidate Cantrixil","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Oasmia Pharmaceutical"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Increases Focus on Clinical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents Novel Supportive Phase I Data at ASCO for its CTLA-4 x OX40 Bispecific Drug Candidate ATOR-1015","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Receives First Patent Approval for ATOR-1017","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience AB (publ) Interim Report January-June 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents the Clinical Project Portfolio at Virtual R & D Day August 27, 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience: Encouraging Interim Safety Data in Ator-1017 Clinical Phase I Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents Positive Biomarker Data Demonstrating Proof of Mechanism in Mitazalimab Clinical Phase I Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Focuses on ATOR-1017 and Mitazalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expected Therapeutic Dose Levels Achieved in Phase I Study with ATOR-1017","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Presents at the SITC 35th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Approved IND for Alligator Bioscience's CD40-Targeting Antibody Mitazalimab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience Submits Cta Application for Mitazalimab Phase II Study OPTIMIZE-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitazalimab Synergizes with Chemotherapy - Alligator Bioscience Presents New Preclinical Data at AACR","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"},{"orgOrder":0,"company":"Alligator Bioscience","sponsor":"Aptevo Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Alligator Bioscience"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
ALG.APV-527 is a bispecific conditional 4-1BB agonist, actuvates upon simultaneous binding to 4-1BB and 5T4. 4-1BB has the ability to stimulate the antitumor-specific T cells and NK cells and 5T4 is an oncofetal tumor associated antigen overexpressed on numerous solid tumors.
Lead Product(s):
ALG.APV-527
Therapeutic Area: Oncology
Product Name: ALG.APV-527
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Aptevo Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 13, 2023
Details:
The initial data demonstrates that DCP-001, an off-the-shelf intradermal dendritic cell-based vaccine was safe and well-tolerated, confirming the benign safety profile of DCP-001 observed in multiple completed and ongoing clinical trials.
Lead Product(s):
DCP-001
Therapeutic Area: Oncology
Product Name: DCP-001
Highest Development Status: Phase I
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 17, 2022
Details:
The antibody CAN04 (nadunolimab) binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. It can counteract contribution of IL-1 system to immune suppressive tumor microenvironment and development of resistance to chemotherapy.
Lead Product(s):
Nadunolimab,Fluorouracil ,Calcium Folinate
Therapeutic Area: Oncology
Product Name: CAN04
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 14, 2022
Details:
Ilixadencel (activated allogeneic dendritic cells) is an off-the-shelf cell-based cancer immunotherapy developed for the treatment of solid tumors, has consistently demonstrated signs of efficacy and maintained a positive safety and tolerability profile.
Lead Product(s):
Activated Allogeneic Dendritic Cells
Therapeutic Area: Oncology
Product Name: Ilixadencel
Highest Development Status: Phase I
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 09, 2022
Details:
Under the terms of agreement, Lonza will provide kilogram-scale synthesis, purification, and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply. Oasmia will leverage Lonza’s extensive experience in manufacturing highly-potent API.
Lead Product(s):
Cantrixil
Therapeutic Area: Oncology
Product Name: TRX-E-002-1
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Lonza Group
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Agreement
March 21, 2022
Details:
Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.
Lead Product(s):
Naptumomab Estafenatox,Durvalumab
Therapeutic Area: Oncology
Product Name: ABR-217620
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
NeoTX Therapeutics
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 30, 2021
Details:
Company initiated its clinical study in solid cancers with birinapant (IGM-9427) in combination with IGM’s DR5 agonist antibody IGM-8444. The purpose of this first clinical trial with the combination will be to explore safety and tolerability.
Lead Product(s):
Birinapant ,IGM-8444
Therapeutic Area: Oncology
Product Name: TL32711
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
IGM Biosciences
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 04, 2021
Details:
NZ-DTX-001 is intratumoural depot formulation of NanoZolid® in combination with docetaxel for treatment of solid tumors.
Lead Product(s):
NanoZolid-Docetaxel
Therapeutic Area: Oncology
Product Name: NZ-DTX
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 04, 2021
Details:
Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.
Lead Product(s):
Tasquinimod ,Ixazomib ,Lenalidomide
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 03, 2021
Details:
In the study, MIV-818 will be administered in two combinations, either with lenvatinib, a tyrosine kinase inhibitor or pembrolizumab, an anti-PD-1 check-point inhibitor.
Lead Product(s):
MIV-818 ,Lenvatinib
Therapeutic Area: Oncology
Product Name: MIV-818
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 31, 2021